Acrivon Therapeutics, Inc.
$1.86
▲
4.11%
2026-04-21 05:04:00
acrivon.com
NGM: ACRV
Explore Acrivon Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$68.97 M
Current Price
$1.86
52W High / Low
$3.56 / $1.05
Stock P/E
—
Book Value
$3.56
Dividend Yield
—
ROCE
-73.75%
ROE
-53.86%
Face Value
—
EPS
$-2.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
74
Beta
1.74
Debt / Equity
2.41
Current Ratio
7.69
Quick Ratio
7.69
Forward P/E
-0.84
Price / Sales
—
Enterprise Value
$-55.43 M
EV / EBITDA
0.67
EV / Revenue
—
Rating
Strong Buy
Target Price
$11.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
| 2. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 3. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 4. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 5. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 6. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
| 7. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -20.12 M | -19.69 M | -22.65 M | -21.66 M | -24.95 M | — |
| Net Profit | -18.98 M | -18.23 M | -21.01 M | -19.68 M | -22.83 M | — |
| EPS in Rs | -0.49 | -0.47 | -0.54 | -0.51 | -0.59 | -0.59 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -84.11 M | -89.2 M | -67.1 M | -32.66 M |
| Net Profit | -77.91 M | -80.56 M | -60.39 M | -31.17 M |
| EPS in Rs | -2.01 | -2.08 | -1.56 | -0.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 129.72 M | 196.59 M | 138.26 M | 181.23 M |
| Total Liabilities | 17.2 M | 19.8 M | 17.07 M | 10.75 M |
| Equity | 112.52 M | 176.79 M | 121.19 M | 170.47 M |
| Current Assets | 120.44 M | 181.63 M | 129.69 M | 132.09 M |
| Current Liabilities | 15.66 M | 17.21 M | 13.3 M | 6.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -63.66 M | -65.67 M | -42.64 M | -30.12 M |
| Investing CF | 66.1 M | -51.77 M | 50.72 M | -141.68 M |
| Financing CF | -0.75 M | 121.03 M | -1.55 M | 101.71 M |
| Free CF | -65.33 M | -68.44 M | -43.93 M | -32.28 M |
| Capex | -1.67 M | -2.77 M | -1.29 M | -2.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -33.4% | -93.76% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.